Loading clinical trials...
Loading clinical trials...
A Phase 1, Open-Label Study of JWCAR029, CD19-targeted Chimeric Antigen Receptor (CAR) T Cells, for Adult Subjects With Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL)
Conditions
Interventions
JWCAR029
Locations
1
China
Ruijin hospital
Shanghai, Shanghai Municipality, China
Start Date
January 5, 2018
Primary Completion Date
December 1, 2019
Completion Date
March 1, 2022
Last Updated
July 12, 2019
NCT05529069
NCT05442515
NCT03938987
NCT03050268
NCT05425992
NCT06365671
Lead Sponsor
Zhao Weili
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions